CA-KONG-INC.
11.5.2021 15:02:10 CEST | Business Wire | Press release
Kong Inc., the cloud connectivity company, today announced the general availability release of Kong Konnect , a service connectivity platform that enables the modern connected business. First previewed at Kong Summit 2020 in private beta , Kong Konnect provides end users with instant access to a comprehensive suite of tools that enable reliable, secure and observable connectivity across their APIs and microservices. The GA release features new multi-geo support, allowing users to physically locate services close to their businesses for privacy and regulatory compliance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005311/en/
The fully modular platform enables developers, architects and operators to accelerate application development cycles and provide connectivity between services for stellar digital experiences. Architects decouple connectivity concerns from microservices so that developers can focus on building applications instead of wasting time building pipes; developers gain architectural freedom to choose the best language, protocol and cloud services for building their microservices; and operators deploy APIs consistently across any infrastructure to support the hybrid or multi-cloud deployment patterns that the business requires for performance, cost, privacy or regulatory compliance reasons.
With the GA release, Kong is introducing a flexible consumption-based pricing model that brings enterprise-class tech within reach of individual developers as well as large teams. Usage of Kong Konnect is metered, enabling users to pay solely for the number of services used.
Kong Konnect is available in three plan tiers:
- Kong Konnect Free allows developers to instantly try out the product without having to go through an enterprise sales representative.
- Kong Konnect Plus offers a freemium model with a pay-as-you-go, credit card-based option that provides a simple way for developers or operators on small teams to quickly start using the services they need right now.
- Kong Konnect Enterprise is for organizations that want to use the platform as a whole; it provides connectivity with enterprise-grade security, scalability and observability across any cloud, platform and protocol to help teams build powerful digital services and experiences.
“Kong Konnect addresses a massive challenge companies face as they enter digital transformation 2.0, which is characterized by an exponential increase in the volume and variety of connections that need to be activated and secured with lightning-fast speed,” said Marco Palladino, CTO and co-founder of Kong Inc. “One day, we will look back in amazement to realize that developers were spending a lot of time building the plumbing, and writing the networking and security code for each service on each platform. Automated cloud connectivity is inevitable – from gateway to service mesh across every cloud, Kubernetes and VMs – and market-leading companies already know this and are offloading this function so that their top talent can focus on application design and feature development so they can continue to outpace the competition.”
A Service Connectivity Platform That Offers Connections for Everyone
With a modular approach, end users can access capabilities delivered as functional modules and provision different types of runtimes on-demand without requiring purchase of the entire platform. Users are able to select and consume only the features they need directly through the Kong Konnect interface, removing barriers to building next-generation applications and services.
Kong Konnect provides reliable, secure and observable connectivity for services across any infrastructure. The SaaS-based management plane accelerates deployments and provides access to functionality modules, including the Kong ServiceHub , Kong Vitals , Kong Runtime Manager and the Kong Developer Portal . Kong Immunity and Insomnia continue to be available for self-management to customers. The runtimes – Kong Gateway and Kong Mesh – are self-managed and provide the flexibility to support any hybrid or multi-cloud deployment pattern.
To get started with Kong Konnect, please visit https://konghq.com/kong-konnect/ .
About Kong Inc.
Kong creates software and managed services that connect APIs and microservices natively across and within clouds, Kubernetes, data centers and more using intelligent automation. Built on an open source core, Kong’s service connectivity platform enables digital innovation by allowing organizations to reliably and securely manage the full lifecycle of APIs and services for modern architectures, including microservices, serverless and service mesh. By providing developer teams with unprecedented architectural freedom, Kong accelerates innovation cycles, increases productivity, and seamlessly bridges legacy and modern systems and applications. For more information about Kong, please visit konghq.com or follow @thekonginc on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005311/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom